Zanzalintinib (zanza) + nivolumab (nivo) ± relatlimab (rela) in patients (pts) with previously untreated clear cell renal cell carcinoma (ccRCC): Results from an expansion cohort of the phase 1b STELLAR-002 study.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Jad Chahoud, Bradley Alexander McGregor, Oscar Reig Torras, Pedro C. Barata, Jonathan Alexander Chatzkel, Simon Yuen Fai Fu, Daniel Castellano, Pablo Maroto-Rey, Julia Martinez Perez, Philippe Barthelemy, Joanna Wojcik-Tomaszewska, Benjamin Garmezy, Marta González Cordero, Mohan Liu, Xinyu Wang, John Russell, Lana Andrianova, Neil J. Shah
Institutions: Moffitt Cancer Center, Dana-Farber Cancer Institute, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, University Hospitals of Cleveland, University Hospitals Seidman Cancer Center, University of Florida, UF Health Cancer Center, University of Auckland, Hospital Universitario 12 De Octubre, Hospital de Sant Pau, Hospital Universitario Virgen del Rocío, Institut de Cancérologie Strasbourg, Sarah Cannon, Bristol-Myers Squibb (United States), Exelixis (United States), Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Exelixis
OpenAlex ID: W4410821641